Cargando…

Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation

The androgen receptor is the main therapeutic target that has been successfully exploited through direct inhibition to extend survival of patients with metastatic castration-resistant prostate cancer (mCRPC). We present a patient who participated in a Phase II study of an antagonist antibody to insu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graff, Julie N, Thomas, George V, Higano, Celestia S, Beer, Tomasz M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2015
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727917/ https://www.ncbi.nlm.nih.gov/pubmed/26848415 http://dx.doi.org/10.7759/cureus.426

Ejemplares similares

Cleistanthins A and B Ameliorate Testosterone-Induced Benign Prostatic Hyperplasia in Castrated Rats by Regulating Apoptosis and Cell Differentiation
por: S C, Santosh Kumar, et al.
Publicado: (2022)

Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials
por: Tarrar, Talha Azam, et al.
Publicado: (2022)

Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial
por: Miyake, Hideaki, et al.
Publicado: (2023)

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
por: Ryan, Charles J., et al.
Publicado: (2021)

Diethylstilbestrol in the Treatment of Castration-resistant Prostate Cancer: A Lower-middle-income Country Experience
por: Ali, Azfar, et al.
Publicado: (2019)

Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol
por: Kvorning Ternov, Klara, et al.
Publicado: (2019)

An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
por: Carles, Joan, et al.
Publicado: (2018)

Metastatic Prostate Adenocarcinoma: A Rare Presentation
por: Rodriguez, Pierre, et al.
Publicado: (2022)

An Unusual Case of Metastatic Prostate Cancer Presenting as a Massive Urinoma
por: Dhawan, Vikas, et al.
Publicado: (2023)

Metastatic Adenocarcinoma of the Prostate to the Brain Initially Suspected as Meningioma by Magnetic Resonance Imaging
por: Son, Young, et al.
Publicado: (2020)

MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer
por: Bhagirath, Divya, et al.
Publicado: (2020)

Unusual presentation of castrate-resistant prostate cancer with urethral and inguinal nodal metastasis
por: Jindal, Tarun, et al.
Publicado: (2021)

Potential use of custirsen to treat prostate cancer
por: Higano, Celestia S
Publicado: (2013)

Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review
por: Sardinha, Mariana, et al.
Publicado: (2023)

Metastatic Prostate Adenocarcinoma Presenting as Acute Quadriplegia: A Case Report and Racial Disparity Analysis
por: Obaed, Nadia G, et al.
Publicado: (2022)

Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial
por: Finelli, Antonio, et al.
Publicado: (2021)

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

Testicular Neuroendocrine Tumors: A Case Report and Literature Review
por: Albalawi, Abdulaziz A, et al.
Publicado: (2023)

Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review
por: Thurtle, David, et al.
Publicado: (2019)

TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment
por: van Elst, Tessa, et al.
Publicado: (2023)

Anti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell–Based Vaccine in Prostate Cancer–Bearing Mice
por: Wei, Si-Ming, et al.
Publicado: (2015)

A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors
por: Qu, Xiaoyu, et al.
Publicado: (2013)

Long-term Survival in a Patient with Metastatic Spinal Cord Compression from a Prostate Cancer with Ultra-high PSA: Case Report and Review of the Literature
por: Nguyen, Nhu Tram, et al.
Publicado: (2015)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Local and systemic morbidities of de novo metastatic prostate cancer in Singapore: insight from 685 consecutive patients from a large prospective Uro-oncology registry
por: Tan, Yu Guang, et al.
Publicado: (2020)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial
por: Connor, Martin John, et al.
Publicado: (2021)

Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort study
por: Ahlberg, Mats Steinholtz, et al.
Publicado: (2022)

Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation
por: Vargas Ahumada, Joel, et al.
Publicado: (2022)

Metastatic prostate cancer men’s attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study
por: Connor, Martin John, et al.
Publicado: (2021)

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
por: Macaulay, Valentine M., et al.
Publicado: (2023)

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
por: Halabi, Susan, et al.
Publicado: (2020)

Prognostic Factors for Prostate Cancer Endpoints Following Biochemical Failure: A Review of the Literature
por: Nguyen, Tim, et al.
Publicado: (2015)

Bilateral Well Leg Compartment Syndrome as a Complication of Prolonged Lithotomy Position in Abdominoperineal Resection Surgery
por: Lee, Bing Howe, et al.
Publicado: (2021)

Focal Cryoablation of the Prostate: Primary Treatment in 163 Patients With Localized Prostate Cancer
por: Khan, Anwar, et al.
Publicado: (2023)

Rarest of the Rare Metastatic Tubulocystic Carcinoma of Kidney
por: Yousuf, Hira, et al.
Publicado: (2020)

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design
por: Freedland, Stephen J, et al.
Publicado: (2021)

Clinical and Histopathological Characteristics of Prostate Cancer Patients Taken to Palliative Transurethral Prostate Resection
por: Rojas-Manrique, Juan P, et al.
Publicado: (2019)

Disseminated Intravascular Coagulation With Excessive Fibrinolysis Following Diagnostic Prostatic Biopsy for Prostate Cancer
por: Ghallab, Muhammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m994jlggkcng743b79vfpnd1c6